FIELD: chemical or physical processes.
SUBSTANCE: invention relates to novel heterocyclic compounds, specifically a benzoimidazole derivative of general formula II, where n equals 0 or 1; X1 is CR5 or N; Y represents C1-C6 alkylene, wherein alkylene is optionally substituted with one or two C1-C3 alkyl; R5 is selected from a group consisting of hydrogen and halogen; R23 is selected from a group consisting of hydroxyl, OR11, -NR7R8, C1-C6 alkyl, C1 haloalkyl, -C(O)NHR11, phenyl, pyridinyl and oxetanyl, wherein each of said phenyl, pyridinyl and oxetanyl is optionally and independently substituted with one or two groups Ra; R24 is selected from the group consisting of hydrogen, C1-C6 alkyl, heteroaryl, selected from pyrazolyl, thiazolyl, oxazolyl, oxadiazolyl and pyridinyl, and heterocyclyl selected from oxetanyl, thiethanyl, thiethanyl oxide and azetidinyl, where each of said alkyl, heteroaryl and heterocyclyl are optionally and independently substituted with one or two groups Ra; R25 is selected from a group consisting of -(V)pR26 and -(V)p-OR14; wherein p is 1, V represents C1-C6 alkylene, wherein alkylene is optionally substituted with 1–3 groups C1-C3 alkyl; R14 is selected from a group consisting of hydrogen and phenyl, where phenyl is optionally substituted with one or two halogen groups or C1 haloalkoxy groups; R26 is selected from a group consisting of hydrogen, C5 cycloalkyl, -OH, -C(O)NH2, -C(O)OR18, -CN, C1 haloalkyl, and groups of formula IIa, where A2 is -O-; A3 represents -O-, -CH2O-, -OCH2-, -C(O)NH-, -C(O)N(R7)-, -N(CH3)- or -NH-; B is selected from a group consisting of phenyl, heteroaryl selected from pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, oxazolyl, benzimidazolyl, quinolinyl, benzoxazolyl, quinoxalinyl, quinazolinyl, imidazopyridinyl, wherein each of said phenyl and heteroaryl is optionally and independently substituted with one or two groups Ra; R7 and R8 independently represent C1-C6 alkyl; R11 is phenyl substituted with one group Ra; R18 represents hydrogen or C1-C6 alkyl; R20 is selected from a group consisting of hydrogen, halogen, C1-C6 alkyl and C1-C6 alkoxy; R21 is selected from the group consisting of hydrogen, halogen and C1-C6 alkyl; R22 is selected from a group consisting of aryl, which is phenyl, and heteroaryl, which is pyridinyl, wherein said aryl is optionally substituted with one group of Ra; Ra independently each occurrence is selected from the group consisting of halogen, C1-C3 alkyl, C3-C6 cycloalkyl, C1 alkoxy, C1 haloalkyl, C1 haloalkoxy, -CH2ORc, -OCH2Rc, -ORc, -CN, -NRbRc, -C(O)NRbRc, -C(O)ORc, heteroaryl selected from imidazolyl and aryl, which is phenyl, wherein each of said alkyl, aryl and heteroaryl are optionally and independently substituted with one group C1-C3 alkyl or halogen; Rb and Rc independently, in each case, are selected from a group consisting of hydrogen, C1-C10 alkyl, C3 and C5 cycloalkyl, phenyl, heteroaryl selected from pyridyl and benzoxazolyl, wherein each of said phenyl and heteroaryl are optionally and independently substituted with one group halogen, C1 haloalkoxy. Also described is a compound of general formula III, where n equals 1; X1 is CR5; Y represents C1-C6 alkylene; R5 denotes hydrogen; R23 is selected from a group consisting of OR11, -C(O)NHR11, C1 alkyl and phenyl optionally and independently substituted with one group Ra; R27 denotes hydrogen or oxetanyl; R11 is phenyl substituted with a group Ra; R28 is selected from a group, consisting of -(V)pR29 and -(V)p-OR14; wherein p is 1, V is C1-C6 alkylene, where alkylene is optionally substituted with one or two groups of C1-C6 alkyl; R14 is selected from a group consisting of hydrogen and phenyl, substituted with one or two halo groups or C1-C3 haloalkoxy; R29 is selected from a group consisting of hydrogen and phenyl substituted with two groups Ra; Ra independently, in each case, is selected from a group consisting of halogen and -ORc; Rc is selected from a group consisting of C1-C10 alkyl and pyridyl substituted with 1–3 halogen groups. Also disclosed is a pharmaceutical composition based on said compounds and methods of treatment.
, 
, 
.
EFFECT: novel heterocyclic compounds which are useful as inhibitors of 5-lipoxygenase and/or prostaglandin E-synthase are obtained.
28 cl, 7 ex, 7 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| PHARMACOLOGICALLY ACTIVE COMPOUNDS AS INHIBITORS OF THE TAM FAMILY RECEPTOR TYROSINE KINASE | 2016 |
|
RU2750727C2 |
| PHARMACEUTICALLY ACTIVE DERIVATIVES OF PYRAZOLOTRIAZINE AND/OR PYRAZOLOPYRIMIDINE | 2019 |
|
RU2818563C2 |
| PYRAZOLOTRIAZINE AND/OR PYRAZOLOPYRIMIDINE DERIVATIVES AS A SELECTIVE CYCLIN-DEPENDENT KINASE INHIBITOR | 2019 |
|
RU2809779C2 |
| QUINOLINE DERIVATIVES AS INHIBITORS OF RECEPTOR TYROSINE KINASE Axl/Mer AND CSF1R | 2019 |
|
RU2812631C2 |
| COMPOUNDS CONTAINING A CLEAVABLE LINKER AND METHODS FOR THEIR USE | 2018 |
|
RU2795168C2 |
| NEUROACTIVE STEROIDS SUBSTITUTED AT POSITION 10 WITH A CYCLIC GROUP FOR USE IN THE TREATMENT OF CNS DISORDERS | 2019 |
|
RU2796006C2 |
| CHIRAL DIARYL MACROCYCLES AS MODULATORS OF PROTEIN KINASES | 2016 |
|
RU2732405C2 |
| N1-(4-(5-(CYCLOPROPYLMETHYL)-1-METHYL-1H-PYRAZOLE-4-YL)PYRIDINE-2-YL)CYCLOHEXANE-1,4-DIAMINE DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF CK1 AND/OR IRAK1 FOR THE TREATMENT OF CANCER | 2018 |
|
RU2761457C2 |
| ACTIVIN RECEPTOR-LIKE KINASE INHIBITORS | 2018 |
|
RU2788628C2 |
| CONDENSED RING HETEROARYL COMPOUNDS AND USE THEREOF AS TRK INHIBITORS | 2015 |
|
RU2708674C2 |
